Skip to main content
Premium Trial:

Request an Annual Quote

IntegriDerm Receives NIH SBIR Grant to Conduct Microarray Skin Disease Research

Premium

IntegriDerm of Huntsville, Ala., was awarded a National Institutes of Health Small Business Innovation Research (SBIR) Phase I research grant to use its DermArray skin biology microarray for research related to skin diseases.

With the $177,165 grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, IntegriDerm scientist Ernest Curto will use the DermArrray to study differences in gene expression between normal skin cells and cells with skin cancer, as well as the effects of different skin treatments on gene expression in keratinocytes, (epidermal cells that synthesize the protein keratin).

The project will also develop specialized array analysis programs for pharmacological and toxicologic data.

“One of the objectives ultimately is to use the data obtained from the first phase to move towards diagnostic product that could be used for more of a clinical setting,” said Thomas Dooley, the company’s CEO.

IntegriDerm, a startup located within 5,000 square feet of Research Genetics’ facilities, focuses on genomics research for dermatology, as well as discovery of new dermatologic products, especially those involved in hair growth and skin pigmentation. Invitrogen, Research Genetics’ parent company, has a minority stake in IntegriDerm, which also has received funding from a previous NIH grant. The company has garnered additional revenues from sales of the DermArray, which it developed in partnership with Invitrogen.

The DermArray includes about 4,400 human genes related to skin biology and 800 ESTs situated on a nylon membrane. The company introduced this product a year ago, and currently sells it for $1,460 per five-time use array to customers within the skin care industry and academia.

To select genes for its DermArray, IntegriDerm uses a proprietary patent pending gene selection technology that Dooley said “gives you a higher probability of giving you an over or under-expressed gene response relative to a randomly chosen gene,” hybridized with your sample.

IntegriDerm recently applied this technology again to select genes for a new pharmacology and toxicology array, winnowing down 40,000 human cDNAs to about 4,400 relevant genes. The company plans to introduce this product, PharmArray, July 1, Dooley said.

— MMJ

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.